跳轉至內容
Merck
全部照片(1)

重要文件

SML1949

Sigma-Aldrich

Synta66

≥98% (HPLC)

同義詞:

4-吡啶甲酰胺, N-(2′,5′-二甲氧基[1,1′-联苯] -4-基)-3-氟-, GSK1349571A, N-(2′,5′-二甲氧基[1,1′-联苯]-4-yl)-3-氟-4-吡啶甲酰胺, S66, Synta 66, Synta-66

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C20H17FN2O3
CAS號碼:
分子量::
352.36
分類程式碼代碼:
12352200
NACRES:
NA.77
暫時無法取得訂價和供貨情況

品質等級

化驗

≥98% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 20 mg/mL, clear

儲存溫度

2-8°C

SMILES 字串

O=C(NC1=CC=C(C2=C(OC)C=CC(OC)=C2)C=C1)C3=CC=NC=C3F

InChI 密鑰

GFEIWXNLDKUWIK-UHFFFAOYSA-N

應用

Synta66已用作:
  • 作为Ca2+释放激活钙 (CRAC)通道抑制剂,研究其对 ORAI 异构体的影响[1]
  • 作为ORAI1阻断剂,研究其对Ca2+进入慢性淋巴细胞白血病(CLL) B细胞的影响[2]
  • 作为CRAC阻断剂,研究其对釉质细胞中钙库操纵性Ca2+内流(SOCE)的影响[3]

生化/生理作用

Synta66(S66)是一种 CRAC(Ca2+ 释放激活型 Ca2+)通道抑制剂,可通过毒胡萝卜素抑制人血管平滑肌细胞(VSMC)中细胞内钙库的 Ca2+ 耗尽,从而高效地阻断 SOCE(钙库操纵性钙内流)(IC50 = 26nM & 43 nM,分别基于最大 Ca2+ 水平 & 增加率)。Synta66 对一系列受体和离子通道(例如 L 型 Ca2 + 通道)没有亲和力,并且不影响 TRPC1/5 介导的 SOCE 或钙库操纵性非选择性阳离子电流。据报道,白细胞对 Synta66 对 CRAC 的抑制作用较不敏感(IC50 = 1.76 μM/HL-60、1 µM/Jurkat,1.4 μM/大鼠 RBL)。
一种选择性的 SOCE 抑制剂,可阻止 CRAC 电流(ICRAC),而没有明显的脱靶效价或亲和力。

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

未看到正確版本?

如果您需要一個特定的版本,您可以透過批號來尋找特定憑證。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Antonio Di Sabatino et al.
Journal of immunology (Baltimore, Md. : 1950), 183(5), 3454-3462 (2009-08-04)
Prolonged Ca(2+) entry through Ca(2+) release-activated Ca(2+) (CRAC) channels is crucial in activating the Ca(2+)-sensitive transcription factor NFAT, which is responsible for directing T cell proliferation and cytokine gene expression. To establish whether targeting CRAC might counteract intestinal inflammation, we
Jing Li et al.
British journal of pharmacology, 164(2), 382-393 (2011-05-07)
The aim was to advance the understanding of Orai proteins and identify a specific inhibitor of the associated calcium entry mechanism in vascular smooth muscle cells (VSMCs). Proliferating VSMCs were cultured from human saphenous veins. Intracellular calcium was measured using
Marjolaine Debant et al.
Journal for immunotherapy of cancer, 7(1), 111-111 (2019-04-25)
Dysregulation in calcium (Ca2+) signaling is a hallmark of chronic lymphocytic leukemia (CLL). While the role of the B cell receptor (BCR) Ca2+ pathway has been associated with disease progression, the importance of the newly described constitutive Ca2+ entry (CE)
Xuexin Zhang et al.
Cell calcium, 91, 102281-102281 (2020-09-09)
The ubiquitous Ca2+ release-activated Ca2+ (CRAC) channel is crucial to many physiological functions. Both gain and loss of CRAC function is linked to disease. While ORAI1 is a crucial subunit of CRAC channels, recent evidence suggests that ORAI2 and ORAI3
Guilherme H Souza Bomfim et al.
Cell calcium, 87, 102187-102187 (2020-03-09)
Calcium (Ca2+) release-activated Ca2+ (CRAC) channels mediated by STIM1/2 and ORAI (ORAI1-3) proteins form the dominant store-operated Ca2+ entry (SOCE) pathway in a wide variety of cells. Among these, the enamel-forming cells known as ameloblasts rely on CRAC channel function

Questions

Reviews

No rating value

Active Filters

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務